【摘要】 目的:观察黄芪及低分子肝素钙联合治疗糖尿病肾病Ⅲ-Ⅳ期患者,在减少尿蛋白漏出,改善低蛋白血症方面的疗效。方法:67例糖尿病肾病患者随机分为两组,对照组32例,采用常规疗法;治疗组35例,在常规治疗基础上加用黄芪联合低分子肝素钙治疗4周。比较治疗前后24 h尿蛋白定量、血浆白蛋白水平。结果:治疗组治疗后24 h尿蛋白定量、血浆白蛋白水平与治疗前比较有显著差异(P<0．05),而对照组相关指标无显著变化。治疗后24 h尿蛋白定量和血浆白蛋白水平,两纽比较亦有显著差异(P<0．05)结论:黄芪联合低分子肝素钙治疗糖尿病肾病Ⅲ-Ⅳ期患者,在减少尿蛋白漏出,改善低蛋白血症方面有一定疗效,故对于延缓肾动能损害进展速度有积极治疗意义。更多还原

【Abstract】 Objective:To observe the therapeutic effects on reducing urine protein when patients,who suffered from diabetic nephropathy(DN)-in stageⅢ-Ⅳ,were treated with Astragalia in combination with Low Molecular Heparin(LMH). Methods: Sixty-seven patients suffered from DN were investigated, which were divided into two groups. The control group and The therapeutic group. The control group including thirty-two patients were treated conventionally. The therapeutic group including thirty-five patients were treated with Astragalia and LMH in four weeks besides from conventional therapy. Compare the level of plasma albumin and urine protein after the patients were treated. Results:In therapeutic group , the quantity of urine protein of twenty-four hours is greatly decreased after they were treated and the level of plasma albumine is the opposite (P<0.05). However, the level of those two index doesn’t change. The level of plasma albumine and urine protein of twentyfour hours in therapeutic group has statistic significarce compared with control group(P<0. 05). Conclusion:It is effective to reduce urine protein and improve hypoalbuminemia, when patients with DN - in stageⅢ-Ⅳ, were treated with Astragalia in combination with LMH. These two drugs play an important role in delaying the progression of renal dysfunction.更多还原